| abstract |
Discloses the use of an antibody that inhibits activation of the complement cascade in the manufacture of a medicament for preventing or treating a pulmonary condition in a subject, wherein said antibody has an active Fab fragment and a mutated Fc portion, wherein the mutated Fc portion does not activate complement, wherein the medicament is suitable for co-administration with an additional active agent, and wherein said antibody is specific to C5, C5 convertase, C5a or C5b-9. Further disclosed is the use of an additional active agent, and pulmonary drug delivery kits comprising said antibody which are formulated for inhalation delivery. |